| 0 (0%) | 12-05 09:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 77.06  |
1-year : | 90.01 |
| Resists | First : | 65.98 |
Second : | 77.06 |
| Pivot price | 52.81 |
|||
| Supports | First : | 54.88 |
Second : | 48.02 |
| MAs | MA(5) : | 54.27 |
MA(20) : | 53.29 |
| MA(100) : | 59.56 |
MA(250) : | 0 | |
| MACD | MACD : | -1.7 |
Signal : | -2.7 |
| %K %D | K(14,3) : | 76.6 |
D(3) : | 60.9 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 78.48 | Low : | 30.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRSP ] has closed Bollinger Bands are 34.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 59.83 - 60.06 | 60.06 - 60.32 |
| Low: | 54.34 - 54.57 | 54.57 - 54.84 |
| Close: | 57.73 - 58.12 | 58.12 - 58.57 |
Fri, 05 Dec 2025
50,250 Shares in CRISPR Therapeutics AG $CRSP Purchased by Philadelphia Trust Co. - MarketBeat
Thu, 04 Dec 2025
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown - MSN
Thu, 04 Dec 2025
Interesting CRSP Put And Call Options For January 2026 - Nasdaq
Thu, 04 Dec 2025
Cathie Wood’s Buys And Rumors Aside, Here’s Why Crispr Therapeutics Is A Strong Buy (CRSP) - Seeking Alpha
Thu, 04 Dec 2025
CRISPR Therapeutics AG $CRSP Shares Bought by Legal & General Group Plc - MarketBeat
Thu, 04 Dec 2025
CRISPR Therapeutics (NASDAQ:CRSP) Nasdaq Index Biotech Momentum - Kalkine Media
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 9.48e+007 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 21,050 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.5948e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 854.7 % |
| Return on Equity (ttm) | -13.3 % |
| Qtrly Rev. Growth | 3.834e+007 % |
| Gross Profit (p.s.) | 27.73 |
| Sales Per Share | -14.73 |
| EBITDA (p.s.) | -2.5039e+008 |
| Qtrly Earnings Growth | -5.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -302 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -3.96 |
| Price to Cash Flow | 4.9 |
| Dividend | 0 |
| Forward Dividend | 2.319e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|